The effectiveness of COVID-19 vaccines was found to be similar for those with a higher body mass index (BMI) and of a healthy weight but slightly lower for underweight people, according to a study published in The Lancet Diabetes & Endocrinology.
Researchers from the University of Oxford compared the risk of severe disease in vaccinated versus unvaccinated people at least 14 days after a second dose.
While overall, the findings showed COVID-19 vaccines significantly reduced the number of cases of the severe disease for everyone regardless of their body size, the effect was slightly lower in underweight people.
Underweight vaccinated people had around half the likelihood of being hospitalised or dying compared with unvaccinated people of the same BMI.
According to researchers, it may be because underweight people were also the least likely to have been vaccinated. It may also reflect a reduced immune response due to frailty or other conditions associated with low body weight. Further research is needed to explore the relationship between BMI and immune responses.
On the contrary, people in the healthy and high BMI groups vaccinated were around 70% less likely to be hospitalised than unvaccinated people. People with a healthy or a higher BMI were also approximately two-thirds less likely to die than their unvaccinated counterparts two weeks after a second dose.
“Our findings provide further evidence that COVID-19 vaccines save lives for people of all sizes. Our results provide reassurance to people with obesity that COVID-19 vaccines are equally as effective for them as for people with a lower BMI, and that vaccination substantially reduces their risk of severe illness if they are infected with COVID-19,” said lead author Dr Carmen Piernas of the Nuffield Department of Primary Care Health Sciences, at Oxford.
“These data also highlight the need for targeted efforts to increase vaccine uptake in people with a low BMI, where uptake is currently lower than for people with a higher BMI,” Piernas added.
For the study, the team included 9,171,524 patients over 18 years old, had BMI data and had not previously been infected with SARS-CoV-2 from December 8, 2020, to November 17, 2021. People were grouped based on their BMI.
Furthermore, the researchers found that people with low and high BMI were at significantly higher risk of severe disease following two doses of vaccine compared with a healthy BMI.
For example, a BMI of 17 was linked to a 50% increase in the risk of hospitalisation compared with a healthy BMI of 23, and a very high BMI of 44 had three times the risk of hospitalisation compared with a healthy BMI.
While the cause of the increased risk among people with obesity is unknown, it is consistent with the higher rate of seasonal flu infections in people with a higher BMI. The team said that an altered immune response in heavier individuals might be to blame.
The above article has been published from a wire agency with minimal modifications to the headline and text.